To include your compound in the COVID-19 Resource Center, submit it here.

Monetizing a slice at a time

One way to get a quicker return on investment, especially in an environment where the IPO market is closed, is to salami slice a company’s assets to monetize the ripest ones first. Thus, it would not be surprising to find other VCs copying the deal structure that Actimis Pharmaceuticals Inc. and Boehringer Ingelheim GmbH put together last week covering the biotech’s

Read the full 614 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers